Structure Therapeutics, Inc.
https://structuretx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Structure Therapeutics, Inc.
IPOs Fizzle Out In The Fourth Quarter
Just three biotech companies floated in the last three months of 2023, but there may be hope for a resurgence next year.
Structure’s Oral Weight Loss Drug Data Underperforms A Big Rival
The company is advancing a Phase II candidate in the closely watched and competitive category of oral GLP-1 receptor agonists for diabetes and weight loss.
Time For Oral Incretins To Prove Their Worth
Several crucial trial readouts in diabetes and obesity will come this year and next, and the stakes are high.
Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
- ADMET
- Bioinformatics
-
Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Basecamp Bio
- Shanghai ShouTi Biotechnology Co. Ltd.
- ShouTi, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice